Affiliation:
1. Department of Pharmacology and Toxicology Indiana University School of Medicine The Stark Neurosciences Research Institute Indianapolis Indiana USA
2. Department of Radiology and Imaging Sciences Indiana University School of Medicine The Stark Neurosciences Research Institute Indiana University School of Medicine Indianapolis Indiana USA
Abstract
AbstractINTRODUCTIONOzone (O3) is an air pollutant associated with Alzheimer's disease (AD) risk. The lung–brain axis is implicated in O3‐associated glial and amyloid pathobiology; however, the role of disease‐associated astrocytes (DAAs) in this process remains unknown.METHODSThe O3‐induced astrocyte phenotype was characterized in 5xFAD mice by spatial transcriptomics and proteomics. Hmgb1fl/fl LysM‐Cre+ mice were used to assess the role of peripheral myeloid cell high mobility group box 1 (HMGB1).RESULTSO3 increased astrocyte and plaque numbers, impeded the astrocyte proteomic response to plaque deposition, augmented the DAA transcriptional fingerprint, increased astrocyte–microglia contact, and reduced bronchoalveolar lavage immune cell HMGB1 expression in 5xFAD mice. O3‐exposed Hmgb1fl/fl LysM‐Cre+ mice exhibited dysregulated DAA mRNA markers.DISCUSSIONAstrocytes and peripheral myeloid cells are critical lung–brain axis interactors. HMGB1 loss in peripheral myeloid cells regulates the O3‐induced DAA phenotype. These findings demonstrate a mechanism and potential intervention target for air pollution–induced AD pathobiology.Highlights
Astrocytes are part of the lung–brain axis, regulating how air pollution affects plaque pathology.
Ozone (O3) astrocyte effects are associated with increased plaques and modified by plaque localization.
O3 uniquely disrupts the astrocyte transcriptomic and proteomic disease‐associated astrocyte (DAA) phenotype in plaque associated astrocytes (PAA).
O3 changes the PAA cell contact with microglia and cell–cell communication gene expression.
Peripheral myeloid cell high mobility group box 1 regulates O3‐induced transcriptomic changes in the DAA phenotype.
Funder
National Institutes of Health